Yervoy (ipilimumab) - BMS
Opdivo (nivolumab) - Ono Pharmaceutical, BMS
Timing of Nivolumab Plus Ipilimumab Administration and Clinical Outcomes in Advanced or Recurrent Non-Small Cell Lung Cancer: A Multicenter Retrospective Cohort Study (ESMO Asia 2026) - Oct 1, 2026 - Abstract #953P; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available 
Clinical data • Metastases • Retrospective data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
https://cslide.ctimeetingtech.com/asia2026/attendee/confcal/print/presentation/1604
 
Ryousuke Kannaka; Yuuichi Adachi; Akihiro Tamiya; Kinnosuke Matsumoto; Tsunehiro Tanaka; Yoshihiko Taniguchi; Naoki Yoshimoto; Takehiko Kobayashi; Motohiro Tamiya; Yoshinobu Matsuda; Kyoichi Okishio
 
Oct 1, 2026
 
Prev Next